Batalla A, Malmary M F, Cambar J, Labat C, Oustrin J
Faculté des Sciences Pharmaceutiques, Université Paul Sabatier, Toulouse, France.
Chronobiol Int. 1994 Jun;11(3):187-95. doi: 10.3109/07420529409057239.
The incidence of cyclosporine A (CsA) nephrotoxicity with reference to the temporal stage of administration was studied during a chronic 21-day treatment in male Wistar rats. Oral administration (20 mg/kg/day) was given at four different times: 1, 7, 13, or 19 hours after light onset (HALO). Plasma creatinine and blood urea nitrogen (BUN) levels were determined at regular intervals over the 24 h: before treatment (day 0); 7, 14, and 21 days after the beginning of treatment (days 7, 14, and 21); and 7 and 14 days after CsA withdrawal (days 28 and 35). At the same times, creatinine clearance and g-glutamyl transferase urinary excretion were determined in the groups of animals treated at 7 and 19 HALO. Residual concentrations of CsA in the renal tissue were measured at the end of the treatment period (day 21) in all groups. Nephrotoxicity of CsA was dependent on the temporal stage of administration. The renal vasoconstriction showed by the increase in plasma creatinine and BUN levels and the decrease in creatinine clearance was maximal when the CsA was given at 7 and 19 HALO and was correlated to the tissue concentrations of CsA. Tubular injury seems to occur earlier and the return to normal function less rapidly in animals treated at 19 HALO compared with animals treated at 7 HALO.
在雄性Wistar大鼠进行的为期21天的慢性治疗期间,研究了环孢素A(CsA)肾毒性的发生率与给药时间阶段的关系。在光照开始后(HALO)的四个不同时间点进行口服给药(20 mg/kg/天):1、7、13或19小时。在24小时内定期测定血浆肌酐和血尿素氮(BUN)水平:治疗前(第0天);治疗开始后7、14和21天(第7、14和21天);以及CsA停药后7和14天(第28和35天)。同时,在7和19 HALO治疗的动物组中测定肌酐清除率和γ-谷氨酰转移酶尿排泄量。在治疗期结束时(第21天)测量所有组肾组织中CsA的残留浓度。CsA的肾毒性取决于给药的时间阶段。当在7和19 HALO给予CsA时,血浆肌酐和BUN水平升高以及肌酐清除率降低所显示的肾血管收缩最大,并且与CsA的组织浓度相关。与在7 HALO治疗的动物相比,在19 HALO治疗的动物中,肾小管损伤似乎更早发生,并且恢复到正常功能的速度更慢。